Gilead's in-line product sales, slight EPS beat and lower expenses were "positive," while the key catalyst for the company's shares will be a "clean and smooth approval" in the United States of ...

Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined. The biopharma's profit got a lift from higher prices and demand for its HIV treatments ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. Gilead Sciences beat analysts’ revenue ...

Gilead Sciences has bolstered its position as a leader in the HIV research space by purchasing an investigational HIV vaccine ...

Gilead's quarterly sales of HIV drug Biktarvy rose 7% to $3.15 billion, roughly in line with Wall Street estimates, while sales of liver disease drugs rose 3% to $758 million. The California-based ...